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Abstract
3,4-Methylenedioxymethamphetamine [(MDMA) or ecstasy] is a popular club drug often used in combination with ethanol. In the
current study, we investigated the effects of MDMA and ethanol combinations on locomotor activity and body temperature of rats. For
four consecutive days, male Long–Evans rats were treated daily with a 10-mg/kg dose of MDMA with or without a 1.5-g/kg dose of
ethanol. 3,4-Methylenedioxymethamphetamine increased spontaneous activity (on average 1,140%), and this increase was potentiated
by ethanol on all days (on average 1,710%). Moreover, ethanol inhibited the MDMA-induced hyperthermia (on average 1.3ºC) by the
first day of treatment, but not on subsequent treatment days, supporting the suggestion that this effect may undergo tolerance. These observations
seem to indicate that combined ethanol–MDMA may induce effects on locomotor activity and thermoregulation that involve separate
mechanisms, the first one being less sensitive to tolerance than the second one might be. Results of our study have important implications
for understanding the motivation and the health risks of polydrug abusers combining ecstasy and ethanol.  2005 Elsevier Inc. All
rights reserved.
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The amphetamine derivative ()-3,4-methylenedioxy-
methamphetamine [(MDMA), ecstasy] has become one of
the most popular recreational drugs of abuse among young
people, particularly in the club culture [see, for example,
Green et al. (1995, 2003) and Schifano (2004)]. In the short
term, MDMA induces release of serotonin and dopamine
in the brain, causes a dose-dependent increase in spontaneous
physical activity, and causes a hyperthermia that may be fatal
in rodents, primates, and human beings (Schifano, 2004). In
the long term, single or multiple high doses of MDMA may
also result in serotonergic toxicity in brain regions, such as
the hippocampus, cortex, and striatum (Green et al., 2003).
The combination of MDMA with various other drugs, such
as amphetamines, cocaine, cannabis, and perhaps predomi-
nantly ethanol, is a frequent pattern of MDMA use in human
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Lora-Tamayo et al. (2004), Pedersen and Skrondal (1999),
and Schifano (2004)]. Moreover, ethanol is known to be one
of the drugs most commonly associated with MDMA [see, for
example, Lora-Tamayo et al. (2004), Pedersen and Skrondal
(1999), and Schifano (2004)]. Until recently, to our knowl-
edge no peer-reviewed journal has published experimental
work addressing the effects of acute ethanol interaction
with MDMA on spontaneous activity or other physiologic
changes such as body temperature alterations in animals.
The only published articles we know about concerning the
effects of MDMA and ethanol interactions are focused on
physiologic or psychologic consequences in human beings:
one on the immune system (Pacifici et al., 2001) and the
other on psychomotor and subjective effects of the drug
combination (Herna´ndez-Lopez et al. 2002). In this article,
on the basis of two approaches, we demonstrate that ethanol
co-administration potentiates the hyperlocomotion induced
by MDMA but prevents its hyperthermic effects. We also
show that the preventive effects of ethanol on MDMA-
induced hyperthermia disappear when what appears to be
tolerance to ethanol develops in the rats. These observations
might have important implications for the health risks of
polydrug abusers who combine ecstasy and ethanol.
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2.1. Subjects
All procedures were conducted in conformity with the
institutional guidelines (council directive 87848, October
19, 1987, Ministe`re de l’Agriculture et de la Foreˆt, Service
Ve´te´rinaire de la Sante´ et de la Protection Animale; permis-
sion 6212 to J.-C.C. and 6714-bis to H.J.; NIH publication,
86-23, revised 1985). Adult, male, Long–Evans rats (3 months
of age; CERJ, Saint-Berthevin, France) were housed indi-
vidually in transparent Makrolon cages (42 × 26 × 15 cm)
under controlled temperature (23ºC) and a 12-h light/12-h
dark cycle (lights on at 7:00 a.m.). The rats were housed
individually because we used them only over a relatively
short period. In addition, grouping males generates fighting,
which might be a potential source of stress and may interfere
with responses to MDMA. The rats were allowed to acclima-
tize to the laboratory conditions for 1 week before the experi-
ment on body temperature was started and 2 weeks before
the activity recordings were performed (see below).
2.2. Drugs
Ethanol [20%, weight/volume] was prepared from abso-
lute ethanol diluted in 0.9% sodium chloride solution and
injected intraperitoneally at a dose of 1.5 g/kg. Intraperito-
neal administration of a 1.5-g/kg dose of ethanol typically
results in a blood ethanol concentration of about 175 mg/dl.
()-3,4-Methylenedioxymethamphetamine (National Insti-
tute on Drug Abuse, Bethesda, MD, USA) was diluted in
0.9% sodium chloride solution and injected intraperitoneally
at a dose of 10 mg/kg. The drugs, whether administered alone
or in combination, were injected in a volume of 7.5 ml/kg,
30 min before the first temperature measures, or 1 to 5 min
before activity recording was started. For the combined
administration, MDMA was dissolved in the 20% ethanol
solution. The dose of MDMA used in the current study was
chosen on the basis of results of preliminary experiments, in
which we found that a single injection of 20 mg/kg was
lethal in 90% of rats [although the 50% lethal dose (LD50)
generally reported for rats in the literature is about 50 mg/kg].
A dose of 5 mg/kg induced effects comparable to those
reported in this article after 10 mg/kg, but their magnitude and
duration were smaller.
On four occasions, 24 h apart, rats were treated with one
of the drugs/combination of drugs for assessment of either
locomotor activity or body temperature measurements.
2.3. Locomotor activity
Spontaneous activity of the rats was measured in their
home cage, and all rats were tested at once. No experi-
menter entered into the room in which activity was measured
during recording. The cages were taken from the colony
room and placed on shelves (eight cages per shelf) in a
separate room (light conditions as in the colony room). Ratshad free access to food and water during activity record-
ing. Each cage contained two crossing infrared light beams
targeted on two photocells, 4.5 cm above floor level and
28 cm apart. The number of crossings in the cage (successive
interruptions of the beams, and thus only two-dimensional
movements) was monitored continuously by a microcom-
puter. Activity was first monitored continuously during the
4 days preceding the first drug administration (data not
shown) to habituate the rats to the conditions of the test room.
After each drug administration, the activity was recorded
continuously for 6 h. The drugs were injected at 12:00 noon.
The ambient temperature during measurements of locomotor
activity was 25ºC 0.1ºC, thus about two degrees higher than
in the colony room. This difference was due to a fortuitous
disturbance of temperature control on the first day, and
we decided to keep that value for the three other days to
ensure as stable as possible experimental conditions for all
activity recording. The final group sizes were as follows:
saline, n 9; ethanol, n  10; MDMA, n 8; and etha-
nol MDMA, n 8. From the initial 10 rats of the MDMA
and ethanol MDMA groups, 2 rats had died in each group
after the first MDMA injection. These rats were different
from those used for body temperature measurements.
2.4. Body temperature
With the exception of the occasions of temperature mea-
surements, rats had free access to food and water. Obser-
vation of the rats’ behavior in their home cage was possible
between each series of temperature measurements. Rectal
temperature was measured with a Pic indolor Vedo Flex
(Artsana-Grandate, Italy) digital thermometer with a 0.1ºC
precision, and the probe was lubricated with petroleum jelly
(Vaseline). Determination of the temperature took a maxi-
mum of 30 s. The first measurement was taken 1 h before
drug treatment (between 11:00 and 11:20 a.m.). The other
measurements were made 30, 60, 120, 180, and 300 min
after drug administration. The ambient temperature during
measurements was 23ºC  0.1ºC. Between measurements,
the rats remained in their home cage. The final group
sizes were as follows: saline, n 5; ethanol, n  6; MDMA,
n 5, and ethanolMDMA, n 7. One rat from the
MDMA group died after the first injection.
2.5. Statistical analyses
All data were evaluated by using analysis of variance
(ANOVA), followed, where appropriate, by multiple com-
parisons with the use of the Newman–Keuls multiple range
test (Winer, 1971). Analysis of body temperature was per-
formed on the temperature changes according to the predrug
temperature. T tests for paired samples were also used for
comparison of average temperatures on days 1 and 2 within
each experimental group.
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3.1. Locomotor activity
The basal locomotor activity for all rats had been recorded
over the first 3 of 4 days of acclimatization to the experimen-
tal conditions. There was no significant difference among
the four groups, in terms of either diurnal or nocturnal
spontaneous home cage activity on each of these days (data
not illustrated). Analysis of the activity scores found on the
6 h that followed the injection (Fig. 1) showed a significant
overall treatment effect on day 1 [F(3, 30) 14.1, P .001],
day 2 [F(3, 30)  25.5, P  .001], day 3 [F(3, 30) 15.5,
P  .001], and day 4 [F(3, 30) 14.6, P  .001]. On day
1, multiple comparisons showed that the treatment effect
was due to a significantly higher activity in MDMA-treated
rats in comparison with their saline-treated or ethanol-
treated counterparts (P  .05), as well as in etha-
nol MDMA–treated rats in comparison with each of the
three other groups (P  .05). The difference between
saline-treated and ethanol-treated rats was not significant
(P  .99). On days 2 and 4, the same between-group differ-
ences were found. On day 3, the only difference from
Fig. 1. Locomotor activity recorded over 6 h after intraperitoneal injection
of a 10-mg/kg dose of 3,4 methylenedioxymethamphetamine (MDMA),
and potentiation of this response by co-administration of a 1.5-g/kg dose
of ethanol (ETH). Injections occurred on four consecutive days, 24 h apart.
Inset shows the activity cumulated over the 4 days (underneath the abscissa,
“” indicates the treatment administered). Means  standard error of the
mean are shown. *Indicates a significant difference in comparison with
saline; **indicates a significant difference in comparison with ethanol,
P  .05; and ***indicates a significant difference in comparison with
MDMA, P  .05.the other 3 days was that the difference between MDMA-
treated and ethanolMDMA–treated rats was not signifi-
cant (P  .27). When the overall activity scores accumulated
over days were compared among groups (see inset, Fig. 1),
we found that ethanolMDMA–treated rats were signifi-
cantly more active than rats of the three other groups (P 
.01), and that MDMA-treated rats were more active than
saline-treated or ethanol-treated rats (P  .001). The differ-
ence between saline-treated and ethanol-treated rats was not
significant (P  .99). In summary, ethanol potentiated the
MDMA-induced hyperactivity.
3.2. Body temperature
Results for analysis of body temperature are displayed
in Fig. 2. For the rats to be injected with saline, the average
basal body temperature (computed over 4 days) 60 min
before the injections was 37.3ºC  0.1ºC and 37.7ºC 
0.1ºC in rats that subsequently received saline and ethanol,
respectively; 37.7ºC  0.1ºC in those to be given MDMA;
and 37.8ºC  0.2ºC in those to be given ethanol MDMA.
There was no significant difference among the four groups
on this variable [F(3, 19) 2.6]. On the first day of injection
after MDMA treatment, the temperature typically had reached
Fig. 2. Body temperature changes recorded 60 min after intraperitoneal injec-
tion of a 10-mg/kg dose of 3,4 methylenedioxymethamphetamine (MDMA),
and reversal of the MDMA-induced hyperthermia by co-administration
of a 1.5-g/kg dose of ethanol (ETH) on the first injection day. Means 
standard error of the mean are shown. *Indicates a significant difference
in comparison with saline; **indicates a significant difference in comparison
with ethanol, P .05; and ***indicates a significant difference in compari-
son with MDMA, P  .05.
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0.1ºC). The temperature had returned to near-normal values
at the postinjection delay of 300 min. It had decreased only
slightly after 120 min. After ethanol injection, the tempera-
ture decreased by about half a degree (0.4ºC  0.1ºC) and
was still close to this value after 300 min (0.5ºC 0.1ºC).
(These findings are not illustrated in this article.) It may be
worth mentioning that from the observations of the behavior
of the rats in their home cage between two measurement
series, it appeared that the behavior of MDMA-treated and
ethanol MDMA–treated rats was similar. The main
changes observed were quantitative only.
Analysis of body temperature changes found 60 min after
injection showed a significant overall treatment effect on
day 1 [F(3, 19) 12.01, P  .001], day 2 [F(3, 19) 9.4,
P  .01], day 3 [F(3, 19) 4.6, P  .05], and day 4 [F(3,
19)  7.7, P .01]. On day 1, multiple comparisons showed
that the treatment effect was due to an increase in temperature
in MDMA-treated rats in comparison with findings for
the three other groups (P  .01), as well as in ethanol 
MDMA–treated rats in comparison with findings for rats
treated with ethanol alone (P  .05). The difference be-
tween saline-treated and either ethanol-treated or ethanol
MDMA–treated rats was not significant (P  .12 and .37,
respectively). On day 2, MDMA-treated and ethanol 
MDMA–treated rats no longer differed significantly from
each other (P  .17). However, the temperature increase
in ethanol MDMA–treated rats was significantly different
from the changes found in ethanol-treated or saline-treated
rats (P  .05), and that of MDMA-treated rats was different
from the change found in ethanol-treated rats (P  .05). On
day 3, the picture was the same, except that only the differ-
ence between ethanol MDMA–treated and saline-treated
rats showed a trend (P  .06), and MDMA-treated rats now
differed significantly from their saline-treated counterparts
(P  .05). On day 4, the difference between ethanol 
MDMA–treated and saline-treated rats was, again, signifi-
cant (P  .05). Results of paired samples t tests showed
that the only significant change on day 2 in comparison
with day 1 was in ethanol MDMA–treated rats (t  4.01,
P .01). In ethanol-treated rats, there was a strong tendency
(t  2.24, P .07). In summary, ethanol prevented the
hyperthermia induced by MDMA on the first injection day,
but not on the three subsequent days.
4. Discussion
Findings of the current study confirm that MDMA treat-
ment induces both hyperlocomotion and hyperthermia in
rats [see also, for example, Cole and Sumnall (2003) and
Mechan et al. (2002)]. To the best of our knowledge, there
is no published report on experimental examination of the
effects of ethanol and MDMA in combination in animals. We
have shown that ethanol acts synergistically with MDMA
to increase locomotor activity in rats, even when adminis-tered repeatedly. In addition, ethanol ameliorates the hyper-
thermia produced by MDMA, but only on the first of
consecutive daily injections. It may be noteworthy that both
these ethanol-induced effects have been replicated in an
ongoing experiment in our laboratory (unpublished observa-
tions, J.-C. Cassel, H. Jeltsch, S. Ben Hamida, J. Koenig,
C. Kelche, and B. C. Jones, 2004), indicating that the data
reported herein are robust. It is interesting that, on the first
day, ethanol potentiated the locomotor effects of MDMA,
whereas it reduced the MDMA-induced hyperthermia. This
finding seems to indicate that this hyperthermia was not a
consequence or a correlate of hyperactivity.
Our observations on both activity and body temperature
are important in that they reveal that the combination of
MDMA and ethanol may have unexpected consequences.
The hyperactivity produced by MDMA taken, for example,
at a rave party may be greatly increased when accompanied
by ethanol, which can be related to the findings on subjective
effects in human beings reported by Herna´ndez-Lopez et al.
(2002). In addition, the apparent protection against the hy-
perpyretic effects of MDMA by ethanol may disappear on
subsequent administrations given in short intervals. The
exact mechanisms of both effects are currently unknown to
us. In rats, ethanol does not cause hyperactivity as it does
in mice [see, for example, Cohen et al. (1997)]. It is, how-
ever, worth mentioning that this synergism is in line with
results that Pacifici et al. (2001) and Herna´ndez-Lopez
(2002) obtained in studies with human subjects. These inves-
tigators showed that physiologic and psychopathologic ef-
fects of MDMA can be increased in the presence of ethanol.
A possible explanation might be that ethanol, for some rea-
sons (e.g., facilitation of the blood–brain barrier permeability
toward MDMA metabolites), has increased MDMA expo-
sure at the brain level. However, this possibility would sup-
pose that all effects of MDMA are increased in the presence
of ethanol, which was obviously not the case with body
temperature in the current study.
As far as that hyperthermia may participate in the neuro-
toxic effects of MDMA, the combined effects on hyperther-
mia pose perhaps an even greater risk. If, on the first occasion
of the use of MDMA, one consumes ethanol, the individual
may indeed be protected against neurotoxic or even fatal ef-
fects. On the second occasion, one may have become tolerant
to the apparent protective effects of ethanol without con-
comitant tolerance to the hyperpyretic effect of MDMA.
Tolerance to ethanol may develop rapidly, and it has been
demonstrated that tolerance to the hypothermic effect of
ethanol may appear as soon as a second exposure to the
drug in a delay of 24 or 48 h after the first one [see, for
example, Chan and York (1994) and Khanna et al. (1993)].
In fact, ethanol is not so much an agent of hypothermia as
an agent that produces poikilothermia (Myers, 1981). Thus,
in a very warm environment (e.g., a rave party in a very
warm room, or even in a hot tub), ethanol may increase the
risk of a fatal hyperthermic crisis. This issue will be ad-
dressed in future experiments.
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In a recent review, Cole and Sumnall (2003) men-
tioned that young people who use ecstasy may also associate
other drugs to protect against the neurotoxic effects of
MDMA. Given that hypothermia may be neuroprotective
[see, for example, Colado et al. (2001)], and if the expected
protection involved hypothermic effects of ethanol or pre-
vention of MDMA-induced hyperthermia, findings of the
current study seem to indicate that this might be true when
ethanol and MDMA are associated for the first time, but no
longer true on subsequent associations, nor after tolerance
to ethanol has developed. In Western countries, in which
many human beings are exposed to small quantities of etha-
nol in early/middle adolescence, it is possible, and even
probable, that preexisting tolerance to ethanol mitigates
this protection against the hyperthermic effects of MDMA
ab initio. Results of the current study demonstrate that com-
bined ethanol–MDMA may induce effects on activity and
thermoregulation that involve separate mechanisms, the first
one being less sensitive to tolerance than the second one.
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